WELIREG®▼ (belzutifan) – Training and Resources
Prescribing Information [External link]
Healthcare Professional Resources
Patient Support Material
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.
For more information on WELIREG visit the product page:
